Bionomics Results Presentation Deck

Adverse Event Summary: Highly Favorable Safety Profile BNC210 225 mg 7 (14.0) BNC210 675 mg 11 (21.6) Number of Subjects With at Least 1 TEAE (%) By Relationship to Study Drug By Severity Possibly/Probably/Definitely (%) 24 Mild/Moderate/Severe (%) Serious Adverse Event System Organ Class and Preferred Term Nervous System Disorders Somnolence (%) Headache (%) Dizziness (%) Gastrointestinal disorders Abdominal pain upper (%) 3/3/0 (6.0/6.0/0) 5/2/0 (10.0/4.0/0) 0 BNC210 225 mg 2 (4.0) 3 (6.0) 1 (2.0) 0 (0) 2/7/0 (3.9/13.7/0) 9/2/0 (17.6/3.9/0) 0 BNC210 675 mg 6 (11.8) 2 (3.9) 3 (5.9) 2 (3.9) Placebo 3 (6.0) 0/2/0 (0/4.9/0) 3/0/0 (6.0/0/0) 0 Placebo 2 (4.0) 1 (2.0) 0 (0) 0 (0) Overall 21 (13.9) 5/12/0 (3.3/7.9/0) 17/4/0 (11.3/2.6/0) 0 Overall 10 (6.6) 6 (4.0) 4 (2.6) 2 (1.3) No serious nor severe adverse events reported The majority of adverse events were reported as mild (17 out of 21) ➤ The 4 moderate adverse events were dizziness and headache (225 mg BNC210); headache and somnolence (675 mg BNC210) Bionomics

View entire presentation